The Factory Floor: Aurobindo Receives Another Form 483
Biocon, Indoco and Lupin Report Successful FDA Inspections
Executive Summary
Aurobindo has received further Form 483s from the FDA, while Biocon has received an EIR for its Bengaluru facility. The FDA has also successfully concluded inspections for Indoco and Lupin, while ANI, Aptar and MicroSphere have made strategic moves.
You may also be interested in...
Aurobindo Splits Out Biosimilars Business
After double-digit growth in formulations sales across geographies in the fourth quarter, Aurobindo expects to continue the momentum this fiscal year. Meanwhile, it might look for partners for its biologics business, which it has now transferred to its fully-owned subsidiary for $48m.
Aurobindo Upbeat On Outlook, Transfers Biologics Biz
After double-digit growth in formulation sales across geographies in the fourth quarter, Aurobindo expects to continue the momentum this fiscal year. Meanwhile, it might look for partners for its biologics business, which is now transferred to its fully owned subsidiary for $48m.
India 2019 – R&D Highs, Compliance Woes And Other Lows
2019 saw Indian companies advance innovation efforts and build and expand their specialty portfolios and biosimilars businesses. But manufacturing compliance issues weighed down several firms while on another front charges against the Singh brothers of Ranbaxy escalated.